Methods and systems for target localization and DBS therapy
Methods and systems are described for detecting if a stimulation lead implanted in a patient's brain has moved. Lead movement occurring between a first time and a second time may be determined by comparing features extracted from evoked potentials recorded at the two times. The disclosed methods and systems are particularly useful for determining if a stimulation lead has moved between the time it was implanted in the patient's brain and the time that stimulation parameters are being optimized. Lead movement during implantation, during parameter optimization, and during or between other lead optimization processes may be determined as well.
1. A method of determining a cause of a decline in therapeutic efficacy of deep brain stimulation (DBS) in a patient having an electrode lead implanted in their brain, the electrode lead comprising a plurality of electrodes, the method comprising:
providing stimulation to the patient's brain using a first one or more of the plurality of electrodes implanted in the patient's brain, wherein the stimulation is configured to provide therapy to the patient,
receiving an indication of a decline in therapeutic efficacy of the stimulation,
determining impedances at one or more of the plurality of electrodes,
sensing evoked potentials evoked by the stimulation using one or more of the plurality of electrodes, and
determining a cause of the decline in therapeutic efficacy based on both the impedances and the evoked potentials.
2. The method of claim 1 , wherein the determining a cause of the decline in therapeutic efficacy comprises comparing the impedances to baseline impedances.
3. The method of claim 2 , wherein the baseline impedances are determined during implantation of the electrode lead into the patient's brain.
4. The method of claim 2 , wherein the baseline impedances are determined during a fitting procedure.
5. The method of claim 1 , wherein the determining a cause of the decline in therapeutic efficacy comprises comparing the sensed evoked potentials to a baseline evoked potential.
6. The method of claim 5 , wherein the comparing the sensed evoked potentials to a baseline evoked potential comprises determining one or more features of the sensed evoked potentials and comparing the determined features to corresponding features of the baseline evoked potentials.
7. The method of claim 5 , wherein the baseline evoked potentials are determined during implantation of the electrode lead into the patient's brain.
8. The method of claim 5 , wherein the baseline evoked potentials are determined during a fitting procedure.
9. The method of claim 1 , wherein determining the cause of the decline in therapeutic efficacy comprises determining if the cause is one or more of (a) migration of the electrode lead, (b) formation of scar tissue at one or more of the electrodes, and (c) progression of the patient's disease.
10. The method of claim 1 , further comprising communicating an indication of the cause of the decline in therapeutic efficacy to an external device of the patient and/or to a remote location via an internet connection.
11. The method of claim 1 , further comprising adjusting a stimulation location on the lead by:
(a) determining an optimized stimulation waveform for evoking a detectable evoked potential by:
using one or more of the electrodes to provide an initial stimulation waveform,
determining if an evoked potential is detectable using one or more of the electrodes,
if an evoked potential is not detectable, adjusting a parameter of the initial stimulation waveform until a first evoked potential is detectable,
(b) determining an optimized longitudinal stimulation position along an axis of the lead by:
providing stimulation at different longitudinal positions along the axis of the lead using the optimized stimulation waveform,
recording a second evoked potential evoked by the stimulation at each of the longitudinal positions, and
selecting the optimized longitudinal stimulation position based on the second evoked potential, and
(c) determining an optimized rotational stimulation position about the axis of the lead by:
at the selected optimized longitudinal stimulation position providing stimulation at different rotational positions about the axis of the lead using the optimized stimulation waveform,
recording a third evoked potential evoked by the stimulation at each of the rotational positions, and
selecting the optimized rotational stimulation position based on the third evoked potential.
12. A medical device configured to determine a cause of a decline in therapeutic efficacy of deep brain stimulation (DB S) in a patient having an electrode lead implanted in their brain, the electrode lead comprising a plurality of electrodes, the device comprising:
control circuitry configured to:
cause stimulation circuitry to provide stimulation to the patient's brain using one or more of the plurality of electrodes implanted in the patient's brain, wherein the stimulation is configured to provide therapy to the patient,
receiving an indication of a decline in therapeutic efficacy of the stimulation,
determine impedances at one or more of the plurality of electrodes,
sense evoked potentials evoked by the stimulation using one or more of the plurality of electrodes, and
determine a cause of the decline in therapeutic efficacy based on both the impedances and the evoked potentials.
13. The device of claim 12 , wherein determining a cause of the decline in therapeutic efficacy comprises comparing the impedances to baseline impedances.
14. The device of claim 13 , wherein the baseline impedances are determined during implantation of the electrode lead into the patient's brain.
15. The device of claim 13 , wherein the baseline impedances are determined during a fitting procedure.
16. The device of claim 12 , wherein determining a cause of the decline in therapeutic efficacy comprises comparing the sensed evoked potentials to a baseline evoked potential.
17. The device of claim 16 , wherein comparing the sensed evoked potentials to a baseline evoked potential comprises determining one or more features of the sensed evoked potentials and comparing the determined features to corresponding features of the baseline evoked potentials.
18. The device of claim 16 , wherein the baseline evoked potentials are determined during implantation of the electrode lead into the patient's brain.
19. The device of claim 16 , wherein the baseline evoked potentials are determined during a fitting procedure.
20. The device of claim 12 , wherein determining the cause of the decline in therapeutic efficacy comprises determining if the cause is one or more of (a) migration of the electrode lead, (b) formation of scar tissue at one or more of the electrodes, and (c) progression of the patient's disease.